Evidence map›Paper›PMID 40777119›Full record

ReviewFrontiers in oncology2025

Differences in the distribution of HER2-positive breast tumors according to ethnicity and genetic variants in

Laura Rey-Vargas, Lina María Bejarano-Rivera, Patricia López-Correa, Diego Felipe Ballen-Lozano, Silvia J Serrano-Gómez

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Laura Rey-VargasCancer Biology Research Group, National Cancer Institute, Bogotá, Colombia.
Lina María Bejarano-RiveraCancer Biology Research Group, National Cancer Institute, Bogotá, Colombia.
Patricia López-CorreaDepartment of Pathology, National Cancer Institute, Bogotá, Colombia.
Diego Felipe Ballen-LozanoClinical Oncology Unit, National Cancer Institute, Bogotá, Colombia.
Silvia J Serrano-GómezCancer Biology Research Group, National Cancer Institute, Bogotá, Colombia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: HER2-positive breast tumors are clinically important breast cancer subtypes with an overall unfavorable prognosis, but also with current optimal treatment options that have significantly improved the patients' survival. Several epidemiological registries have reported varying prevalence rates of HER2-positive breast tumors among population groups. In this review, we describe the prevalence of HER2-positive breast tumors by ethnicity, with a special focus on Asian and Latina women, along with genetic variants located in or near Methods: We conducted a literature search for studies reporting differences in HER2-positive breast tumor prevalence among populations and HER2/ Results: Overall, Asian and Latina women tend to have higher proportions of HER2-amplified tumors, compared to non-Hispanic white (NHW) women. Additionally, higher Indigenous American ancestry is associated with an increased likelihood of HER2-positive tumors and elevated Conclusions: This literature review contributes to a better understanding of the underlying biology of HER2 expression in breast tumors, and the possible mechanisms that explain the differences in the distribution of HER2-positive subtypes among various population groups.

Indexed as

American Native Continental Ancestrybreast neoplasmsethnic groupHER2 genesingle nucleoside polymorphism

Identifiers

PMID40777119
PMCPMC12328178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.